New protein function could explain cause of neurological disease

Linking actin bundling to Charcot-Marie-Tooth Disease

Banner image: Time-lapse image showing free actin filaments (left) gradually being organized into bundles and cables by the tyrosyl-tRNA synthetase.

Antwerp, 9 March - The nerves in your body make you move, feel, and think. CMT, or Charcot-Marie-Tooth disease, is an inherited and incurable neurological disease that occurs in one in every 2500 people. The disorder affects the nerves in your limbs, making it hard to move. More than 100 genes have been linked to CMT, but researchers remain largely in the dark about how these genes could cause the disease. Now, the lab of Albena Jordanova (VIB-UAntwerp Center for Molecular Neurology) sheds light on this. They found that a group of proteins that help build cells also have another job: making tight bundles of actin fibers in the cells. When these proteins don't work correctly, they can damage the nerves and cause the symptoms of CMT. Their work was published in the leading journal Nature Communications.

Albena Jordanova: "Our findings expand the current knowledge of textbook enzymes and provide a new framework on how to explain diseases like CMT. We hope that future studies will build on our research and help develop new treatments for this disease."

The most common rare disease

CMT, or Charcot-Marie-Tooth disease, is an inherited disease that affects nerve cells. Patients usually experience the first symptoms at a younger age, starting in the lower limbs, where muscle strength decreases. They also experience loss of sensation and develop skeletal deformities. CMT affects about 2.5 million people worldwide and around 3500 in Belgium. This makes it the most common rare disease.

More than 100 genes have been implicated in CMT. They are involved in various processes, making it a complicated disease to study. Previously, the group led by Albena Jordanova showed that one class of proteins, tRNA synthetases, are associated with CMT and that defects in these proteins could cause nerve damage in CMT by interfering with the gene transcription in the nucleus. However, how they cause the disease remained unknown. The Jordanova-lab now identified another disease-related function that can be attributed to synthetases and potentially explain CMT and similar neurodegenerative disorders. This discovery is a step forward toward a remedy for these diseases.

Albena Jordanova (left) and Biljana Ermanoska (right)

A new biological function

Producing proteins is one of the most essential tasks of the cells in your body, and tRNA synthetases play a significant role. These proteins ensure the correct building blocks are stacked onto a growing protein as it is made. They are constantly at work in every cell of the body. Mutations in these tRNA synthetases are associated with CMT, but strangely enough, they hardly disrupt this essential "block-building" function. This led Jordanova's team to suspect another function of these synthetases.

The researchers discovered that tRNA synthetases don't just build proteins but also make tight bundles of the actin fibers present in cells. These fibers are part of the cell's cytoskeleton, defining its shape and motility. Just like tying together multiple strands of rope creates a stronger and more stable structure, bundling actin filaments creates a larger, more robust skeleton structure that can support the cell. The problem is that defective synthetases may over-bundle actin filaments, impairing proper nerve function and causing CMT. This interference was found in both fruit flies and human cells. Excitingly, modulating the neuronal actin cytoskeleton improves the symptoms of sick flies. This supports the hypothesis that the actin cytoskeleton is involved in CMT, which may have tremendous therapeutic implications for patients.

Biljana Ermanoska, first author of the study, concludes: "Studying essential proteins comes with numerous challenges, which we tackled by adopting interdisciplinary approaches supported by the international teams of collaborators. I am excited to see future studies that will build on our findings and potentially bring together synthetases, actin dynamics, protein translation, and neurodegeneration."

Publication

Tyrosyl-tRNA synthetase has a non-canonical function in actin bundling. Ermanoska, et al. Nature Communications, 2023. DOI/10.1038/s41467-023-35908-3


Questions from patients 

A breakthrough in research is not the same as a breakthrough in medicine. The realizations of VIB researchers can form the basis of new therapies, but the development path still takes years. This can raise a lot of questions. That is why we ask you to please refer questions in your report or article to the email address that VIB makes available for this purpose: patienteninfo@vib.be. Everyone can submit questions concerning this and other medically-oriented research directly to VIB via this address.

About the VIB-UAntwerp Center for Molecular Neurology

Neurodegenerative diseases such as Alzheimer's, epilepsy, and neuromuscular disorders are a major challenge for our society. Research at the VIB-UAntwerp Center for Molecular Neurology begins by studying patients and their family members in order to gain new insights into how these diseases start and develop. Thanks to this knowledge, new therapies can be developed.


India Jane Wise

India Jane Wise

Science Communications Expert, VIB
Joran Lauwers

Joran Lauwers

Press Contact, VIB

Read more

Website preview
The woman and science behind an incurable disease
An interview with a patient and the researchers studying her disease
blog.vib.be

 

 

Share

Latest stories

Website preview
Blocking lipid production in healthy lung cells can reduce lung metastasis
Leuven, 17 March 2026 - Scientists from the VIB–KU Leuven Center for Cancer Biology, in collaboration with the Francis Crick Institute, have discovered how cancer cells can exploit healthy lung cells to support metastatic tumor growth in the lungs. In two complementary studies published in Nature Cell Biology and Cancer Discovery, they show that tumors use lipids produced by lung cells as signals, and that decreasing the lipid production of lung cells can decrease metastasis. The findings point to new therapeutic strategies that target lung cell lipid production, rather than cancer cells themselves, which may also help refine patient selection for ongoing clinical trials targeting this pathway.
press.vib.be
Website preview
Researchers identify major genetic risk factor for rare form of dementia
Antwerp, 12 March 2026 - Researchers at VIB and Antwerp University have identified a major genetic risk factor for a rare form of frontotemporal dementia. The discovery, published today in Nature Genetics, provides a biological entry point for a disease subtype that has been difficult to study. It could not only help to improve diagnosis and patient stratification, but also opens up new avenues toward targeted treatments.
press.vib.be
Website preview
Protealis Announces Regulatory Approval of its First Biological Solution MagNfixTM and Launch of Five New Soybean Varieties
Ghent (Belgium), 11 March 2026 – Protealis, the European specialist in non-GMO legume seeds and seed technologies, today announces several milestones that significantly strengthen its position in a fast-growing European soybean market. The company has obtained European regulatory approval from EFCI1 (EU Fertilising Products Regulation (FPR) 2019/1009) for MagNfix™, its first biological solution, which is a proprietary soybean inoculant seed coating that is designed to support higher soybean yield and protein content. In addition, Protealis has secured the registration of five new soybean varieties across four European countries. This includes the introduction of two new maturity group (MG) 000 soybean varieties in Poland, the registration of its first maturity group 0000 ultra-early soybean variety in France, and a new soy variety registration for Belgium. In Germany, Protealis received registration for its second 00 MG soybean variety suited for the regions in southern Germany...
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be